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ABSTRACT

Streptokinase-activated fibrinolysis of platelet-poor citrated
dog plasma was studied by thrombelastography before, during, and
after administration of choline.

Plasma samples were tested in

several clot-lysis systems containing:

1) human plasma or

euglobulins for providing proactivator and needed clotting factors
for hemophilic plasma;

2) varying concentrations of streptokinase;

3) calcium chloride.
Three hemophilic (Factor VUI-deficient) and four normal
dogs were treated with choline for periods of 3 - 15 days during
a 10-month study.

The choline (as dihydrogen citrate), administered

perorally at 5 times normal dietary level, significantly increased
fibrinolysis times within 24 hours in all of the dogs tested.
Dosage with citric acid, for control purposes, did not cause
prolongation of fibrinolysis.
Explanation of previously reported beneficial effects of
choline-containing peanut extracts in hemophilia is discussed in
terms of the effect on fibrinolysis reported here.

It appears

that high choline dosage should permit a more effective hemostatic
clot in hemophilia.

Observations on bleeding episodes of the

hemophilic dogs used in this study give further support for the
antifibrinolytic effect of high choline dosage.
vi

INTRODUCTION

Hemophilia, in addition to its occurrence in humans, has been
reported in horses (Sanger, Mairs, and Tropp, 1964), swine (Cornell
and Merkner, 1964) and in dogs (Field, Richard, and Hutt, 1946;
Mustard et al., 1960; Mustard et al., 1962; Brock et al., 1963;
Didisheim and Bunting, 1964; Kaneko, Cordy, and Carlson, 1967).
Clinical treatment and establishment of colonies for hemophilic
dogs have been described (Graham et al., 1949; Sharp and Dike, 1964;
Brock et al., 1963; Bird et al., 1964).

The latter 2 reports were

on the colony at Oklahoma State University, Stillwater, from which
the dogs used in this research were obtained.

Brinkhous and

Graham (1950) described hemophilia in the female dog and Parks et al.
(1964) recount laboratory detection of female carriers of canine
hemophilia, in the colony at Chapel Hill, North Carolina, described
by Graham et al. (1949).

Canine hemophilia has been shown to have

many similarities to hemophilia in man and has also been shown to
be a sex-linked inherited deficiency of factor VIII activity in some
of the dogs, as those in the colonies listed above at Chapel Hill
and Oklahoma.

Dogs from the Oklahoma colony formed the nucleus of

the colony established at Louisiana State University and were used
in the present study for testing the possible beneficial effect
that choline may have on their bleeding tendency.
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The idea of the use of choline as an aid in controlling mild
bleeding episodes in hemophilia had its origin in the work by
Boudreaux and Frampton (1960).

Boudreaux, a factor VIII-activity

deficient hemophiliac, observed that the tenderness of an acute
hemarthritic knee seemed to subside after the ingestion of roasted
peanuts.

A series of experimental investigations followed to try

to explain how peanuts could provide clinical relief from bleeding.
Since no change in the coagulability of the blood could be found
(Schmutzler, 1961) other explanations for the possible beneficial
effect of peanuts were postulated.

Ethanolic extracts of

defatted peanuts (Boudreaux et al. 1960, Frampton et al. 1966)
were further separated by solvent separation and by chromatography
into fractions, one of which was reported to shorten bleeding time
in hamsters.

Astrup et al. (1960) suggested that the possible

effect of peanuts is the shifting of the hemostatic balance in the
organism due to pro tease inhibitors present.

Pro tease inhibitors

had been known to be present in peanuts since Borchers' report in
1947.

Astrup et al. suggested that, acting as

antifibrinolytic

agents, such inhibitors could delay resolution of small fibrin
deposits and thus improve hemostasis.

Van Creveld and Mochtar (1961)

as well as Moers and den Ottolander (1961) demonstrated shortened
euglobulin clot lysis times in hemophilic patients consuming
peanut products.

Nilsson (1960) reported an antifibrinolytic

effect using streptokinase and plasma from hemophilic patients who
had ingested roasted peanuts.

Schmutzler (1961) found a small amount
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of antifibrinolytic activity in ethanol extract from peanuts.
Brahman, Sj^lin, and Astrup (1962) reported a decrease in
spontaneous fibrinolytic activity with peanut administration.
Bisordi (1964) reported clinical benefit in hemophiliacs treated
with peanut flour.

A potent antifibrinolytic substance extracted

from peanut skins was claimed by Sepelak (1963) to promote hemostasis
in hemophilia and other hemorrhagic states.

Novak (1966) indicated

that peanut extract injected intravenously inhibited fibrinolysis
in dogs.
Frampton et al. (1966) processed peanuts through an extended
series of extractions and chromatographic separations in an effort
to isolate the active hemostatic material.

Jackson, Owen, and

Boudreaux (1966) on the basis of pharmacological and chemical studies
on fractions derived from alcoholic extracts concluded that
clinical improvement afforded hemophiliacs by consumption of peanuts
or its extracts may be attributable to choline.

Boudreaux is

apparently controlling his bleeding tendency by using 8 grams
daily of choline dihydrogen citrate.
A known inhibitor of fibrinolysis,

epsilon-aminocaproic acid

(EACA) has been used therapeutically in normal and hemophilic
cases (Reid et al., 1964; Mainwaring and Keidan, 1965; Reid et al.,
1965; Nilsson, 1966; Reid, Hodge, and Cerutti, 1967).

An even

more powerful inhibitor, trans-4-amino-methylcyclohexane-l-carboxylic
acid (AMCHA) is currently claiming the interest of workers in this
field.

Results of an in vivo study using dogs have recently been

published (Celander and Celander, 1968).

Although drawing general conclusions from experimental animals
is difficult due to the large quantitative and qualitative dif
ferences between species (Astrup, 1969), testing the fibrinolytic
inhibition of choline on hemophilic dogs seems worthwhile.

Byshevsky

(1965) exhibited inhibition of fibrinolysis in dogs with intravenous
injections of choline.

The purposes of my research was to test the

antifibrinolytic effect of choline administered perorally to both
hemophilic and normal dogs and to observe possible clinical benefit
to the hemophilic dogs.
Thrombelastography (Hartert, 1951) was the choice for study
of both the formation and dissolution of the clot formed from dogs
administered choline.

This method has been used to study hemophilia

(de Nicola and Mazzetti, 1956; de Nicola, 1957a; de Nicola, 1957b)
and shown to be a good system for studying fibrinolysis (Von Kaulla
and Weiner, 1955; Von Kaulla, 1957; de Nicola and Mazzetti, 1957;
Von Kaulla and Schultz, 1958; Astrup and Egeblad, 1965).

The effect

of EACA and the trypsin inhibitor in peanuts on fibrinolysis in vitro
were demonstrated with thrombelastography (Egeblad, 1966, 1967a and
1967b).

The role of fibrinolytic inhibitors on hemophilia was

tested by Reid et al. (1965) also using thrombelastography.
** ’ •

They

'.kV

found that EACA had a normalizing effect On the hemophilic
thrombelastogram.
Normal values for the thrombelastograms in dogs were reported
by Popisil (1966) but normal values for thrombelastograms of
streptokinase-activated fibrinolysis in the normal or hemophilic dog
could not be found in the literature.

Studies on fibrinolysis in
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the dog such as Holemans1 study (1965) and on the effect of AMCHA
on fibrinolysis by Celander and Celander (1968) were helpful.

Very

high platelet numbers may have either a fibrinolytic (Holemans and
Gross, 1961a and 1961b) or an antifibrinolytic (Johnson, 1953 and
Stefanini, 1956) action.

Only small numbers of platelets were

used in the present study, minimizing the effect of platelets on
fibrinolysis.
Streptokinase-activated fibrinolysis by means of thromb
elastography (de Nicola, 1957; Astrup and Egeblad, 1965) was the
chosen method for measuring fibrinolysis after choline treatment
of the dogs.

Reviews (Sherry, and Alkjaersig 1958; Sherry,

Fletcher, and Alkjaersig, 1959; Sherry, 1968; Astrup, 1969)
suggest that SK-activated fibrinolysis is a useful system for
measuring inhibitors of fibrinolysis.

By using thrombelastography,

other parameters of the clot, such as clot firmness (Weiner and
Weisberg, 1957), could be observed simultaneously for differences
that might occur due to choline.
It was kept in mind that if choline has a favorable influence
in hemophilia it might have an unfavorable one in normal animals.
In studies done on rats primarily to test the effect of butter and
c o m oil on the lytic phase of thrombelastograms, but which employed
diets with high choline levels, pathological conditions associated
with prolonged fibrinolysis times developed (Tillman et al., 1960;
Lee et al., 1962; Kim et al., 1963; Lee, Kim, and Sherman, 1963;
Kim et al., 1964; Kim, Lee, and Thomas, 1965; Nam et al., 1965).
Many suggestions are brought forth to explain the above phenomenon.
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Beta-lipoproteins have been shown to have antifibrinolytic activity
(Skrzydlewski and Niewiarowski, 1966; Riding and Ellis, 1964) and
are elevated in atherosclerotic sera (Sarkar, 1961).
choline is associated with these two phenomena.

Perhaps

But again one must

be extremely careful in generalizing from one animal system to
another.
The measurement of the beneficial effects and mechanism of
action were the main aims of this research.

If choline can be

shown to be hemostatic in hemophilic dogs, then further studies
using human subjects would be in order.

MATERIALS AND METHODS

General design and plan of work.

Streptokinase (SK) -activated
I

fibrinolysis was studied by thrombelastography in 5 normal and 3 hemo
philic dogs.

Blood samples were collected when the only source of

choline was that provided by the diet and also while extra choline was
given perorally.

Six separate periods of choline treatment (3 - 15

days' duration) were used during the 10-month study.

In 4 of the

periods, 6 dogs were treated; in 1 case, 1 dog only; in the remaining
period, 2 dogs.

For choline dosage, commercially available tablets

containing 600 mg choline dihydrogen citrate were used.

Four times

daily, each dog was made to swallow a tablet or a half-tablet, depending
on body weight and desired dose.

In certain test periods, doses of

300 mg choline citrate per 17 - 20 lb body weight were given (1200 mg/
day for the adult dogs).

In other treatments, the dosage was twice

this amount.
For control purposes, 2 test periods were provided during which
time the dogs were given citric acid 4 times daily, in quantities
equivalent to those of the citrate provided in the tests with choline
dihydrogen citrate.

Also, for some comparison of the effect of choline

on SK-activated fibrinolysis with that produced by a better-known
inhibitor of fibrinolysis, two short experiments were run with EACA.
In each of these, 2 dogs were given, perorally, single doses of
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0.34 mg/kg body weight.

Blood samples were taken in one experiment

3 hours after the EACA; in the other experiment, after 7 hours.
An essential part of this study was investigation of the
composition of clotting-lysis mixtures suitable for thrombe
lastographic studies with hemophilic dog plasma.

For promptness

in clotting of hemophilic plasma and achievement of a satisfactory
maximum amplitude, inclusion of the deficient clotting factor was
essential.

For SK-activation of the fibrinolytic system of the

dog, a source of proactivator from human plasma was required.
Dogs;

source; status with regard to hemophilia; maintenance.

The 8 dogs used in this work were members of an inbred colony of
beagles.

Three were originally from the Stillwater, Oklahoma colony

of the School of Veterinary Medicine, Oklahoma State University; the
remaining 5 were born in the newly established LSU colony.
Information on the individual animals is given below:
G-3,

hemophilic $, obtained

as adult, Nov. '67

G-4,

hemophilic cf, obtained

as adult, Nov. '67

V-l, normal cf, obtained as adult, Aug. '67
K-l,
normal cf's, born at LSU, Jan. '68, from mating of T-4

K-2,
(carrier obtained from Stillwater) and G-4
K-3,
K-9,

normal cf, born at LSU, Jan. '69, from mating ofT-4

A-l,

hemophilic cf, born at LSU, Sept.

and G-4

'68, frommating of G-3

and G-4
The adult beagles weighed 17-20 pounds.

Three of the younger

dogs weighed about half this amount when they were first used in
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experimental work; when they were next studied, they had reached adult
weight.
The hemophilic or normal states of the dogs furnished by
Oklahoma State University and the dogs born in the LSU colony were
verified by tests conducted in this laboratory.

The dogs with bleeding

disorders were shown to have classical canine hemophilia; i.e.,
deficient Factor VIII-activity, as indicated by the following tests:
Lee-White clotting time, prothrombin time, partial thromboplastin time,
and thromboplastin generation time.

Results from thrombelastography

of whole blood (following procedures according to Marchal, Leroux, and
Samana, 1963) supported diagnoses of clotting defect (Fig. 1).
The dogs were housed in the LSU Canine Hemophilia Laboratory, a
small air-conditioned building used exclusively for these studies.
They were caged individually in the main kennel room, and each dog
had its own outside runway (in an adjoining semi-enclosed area suitably
protected against weather and insects).
attended and fed twice daily.
Prescription Diet®

The animals were regularly

Each adult dog received 40g ez/d

and 160g f/d Prescription D i e t ® (Mark Morris

Associates, Inc., Topeka, Kansas) per day.

The quantity of ration

described above provided 220 mg choline.
Bleeding procedure; preparation of citrated samples.

The dogs

were bled immediately after the morning feeding to avoid lipemia and
shift of fluid from the blood into the digestive tract.

The dogs

were less excitable and easier to handle for venipuncture after feeding.
Three to five ml of blood was carefully drawn from the jugular vein
into a siliconized glass syringe equipped with a 20-gauge disposable

V-l
G-3
20mm

Fig. 1. 'Thrombelas tograms of whole blood from hemophilic dog (G-3) and normal dog (V-l).

stainless steel needle.

When the jugular vein was not entered with,

the first puncture through the skin, then the needle was replaced with
a new one and the opposite vein used, minimizing tissue fluid contamin
ation.

Blood was withdrawn smoothly, at a rate of about 0.5 ml/sec.

The needle was removed from the syringe and blood was dispensed into
a siliconized calibrated test tube (12 mm diameter) containing the
proper volume of ice-cold 3.8% sodium citrate solution required for
a dilution of 9 parts blood with 1 part citrate solution.

Blood

remaining in the syringe was used for microhematocrit and some whole
biood platelet counts.

All citrated blood samples were kept in an

ice bath until they were given special processing or directly used
in tests, and every effort was made to avoid delay in the work.

No

samples were used that were more than 4 hours old.
Platelet-poor plasma for Thrombelastographic studies.

Citrated

blood samples were centrifuged at 3000 rpm (1500 g) for 10 min, using
a Servall RC-2 centrifuge equipped with a HB-4 head and set for 4° C.
Each plasma sample was promptly transferred by pipette into a cold
test tube and kept in an ice bath.
of plasma was siliconized.

All glassware used in handling

Counts were made to validate consideration

of the plasma as "platelet-poor."

With almost 200 samples, platelet

number was not higher than 12,000/mm

in 85% of the cases; slightly
q

more than half of the counts were in the range of 3,000-7,000/mm
(Fig. 2).
Platelet counts.

The procedure used for whole blood was that

described by Brecher, Schneiderman, and Cronkhite (1953).

With

samples of platelet-poor plasma prepared from citrated blood, counts

t

A -1
;■«,I.viw
^

20min

rrygy^£>aaac»fla>afeS3^jgg3t^£C3a%sa^^

|

20mm

Fig. 2.

Thrombelastograms of platelet-poor plasma from hemophilic dog (A-1) and normal dog (V-l).

-
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were made without further dilution, and the appropriate factor used

.

in calculating number of platelets per m m ,
Special reagents.

Owren1s modified barbital buffer, pH 7.35,

ionic strength of 0.154: 0.1N HCl, 43.0 ml; sodium veronal (diethylbarbital), 1.175 g; NaCl, 1.467 g; deionized water, to 200 ml (Owren,
1947).

I

Gelatin-barbital buffer. 0.25%:

0.25 g gelatin (175 Bloom,

General Biochemicals) per 100 ml Owren1s modified barbital buffer;
stored at 4° C.
Streptokinase (Varidase, Lederle).

Stock solutions were prepared

by diluting 1 vial of SK (20,000 units) with gelatin-barbital buffer
to concentrations of either 1,000 or 2,000 units/ml.

The solution

was sub-divided into 0.1 ml volumes and stored at -20° C.

For each

run a new vial was used, in some cases further dilutions being
required.
Choline dihydrogen citrate (Eli Lilly and Co.).

600 mg tablets,

No. 1697.
i

Epsilon-amino-caproic-acid (Sigma Chemical Co.).

EACA dosage

prepared by placing proper amount of crystals in gelatine capsule.
Plasma euglobulin fraction (human) for use with streptokinase.
Lyophilized human plasma ("Anti-Hemophilic Plasma", Hyland Labora
tories, Lot 260A168) was subdivided into 90-mg aliquots, equivalent
to 1 ml original plasma plus the citrate used as anticoagulant.
Weighings were made directly into small vials suitable for storage at
-20° C and for reconstitution.

Freshly separated euglobulins from

these vials were prepared in the usual manner (see below) after

14

adjustment of the diluted plasma to pH 5.4.

After centrifugation,

the euglobulins were reconstituted to 1/5 original volume of plasma
with gelatin-barbital buffer.

Beginning with System 5, a more

efficient method was employed, and a higher pH (5.9) for the
precipitation step was used.

This second lot of the Hyland material

(Lot 260X25), equivalent to 82 ml original plasma, was reconstituted
after precipitation and centrifugation in 4.2 ml gelatin-barbital
buffer, divided into 0.1 ml aliquots, lyophilized and stored at -20° C.
For use as a component in an SK-containing mixture for thrombelasto
graphy, the contents of a single vial were dissolved in 100 ;il
deionized water and kept in an ice bath.

Desired volumes were

transferred to the TE cuvettes as needed.
Euglobulin clot lysis times.

Platelet-poor citrated plasma,

0.5 ml, was diluted 1:19 with cold deionized water, 9.5 ml, ;'(4a .C).
The pH of the diluted plasma was brought to 5.4 by addition of 1%
acetic acid.

The plasma was stored for 15 min at 4° C and then

centrifuged for 10 min at 3,000 rpm (1,500 g).

The precipitate was

reconstituted to original volume of citrated plasma with Owren's
modified buffer, pH 7.35.
50 pi of 1.25% CaCl2 »

The solution was clotted by addition of

The clotted euglobulins were put in a water

bath of 37° C and observed every 5 min until the clot was totally
lysed.

The time necessary for dissolving of the clot was recorded.

Preparation of clotting-lysis mixtures for study by thrombelastography.

Five different systems were used.

human plasma, the procedure was the following:

For those containing

Into a prewarmed

test tube (10 x 75 mm) kept in a 37° C water bath, desired volumes
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of the components were added in rapid succession:

2 volumes of

platelet-poor citrated dog plasma; 1 volume of reconstituted human
plasma (Ortho-Diagnostic); 0.1 volume of SK-mixture; and 0.3 volume
of 1.29% CaCl 2 solution (warmed).
of the calcium chloride.
mixing of its contents.

A timer was started upon addition

The test tube was inverted several times for
Immediately after, 0.35 ml of the mixture

was transferred to the temperature-equilibrated TE cuvette, the
appropriate pin was lowered, and the surface of the sample covered
with oil.

When the timer read 60 sec, the light for that cell was

turned on.
Composition of the 3 mixtures containing human plasma differed
in only one important respect: namely, concentration of SK in the
system.

These concentrations were 14.7, 38.5, and 29.1 SK units/ml

final mixture in Systems 1, 2, and 3, respectively.

Volumes of the

several components used in System 1 were the following:

0.40 ml dog

plasma, 0.20 ml human plasma, 20 pi SK-mixture containing 10 units SK;
60 pi CaCl2 solution.

Systems 2 and 3 were prepared with volumes of

components proportional to those given above, but total volumes were
reduced slightly.
With mixtures containing human euglobulins (Systems 4 and 5),
the following procedure was used.

Into the thrombelastograph cuvette

(37° C), the components other than calcium chloride were added in
rapid succession.

A stop watch was started upon transfer of the first

component, 0.25 ml platelet-poor dog plasma; addition of 25 pi each
of a human euglobulin preparation and of a diluted SK-mixture followed.
At precisely 2 min after transfer of the dog plasma, 50 pi CaCl2

(1.29%) was added, and the pin lowered and raised 3 times for mixing.
The pin was lowered once more, and the surface of the liquid covered
with oil.

At 3 min after the starting of the stop watch, the light

switch for the cuvette was turned on.
As indicated previously, 2 different preparations of euglobulins
were used.

Also, relative concentrations of the euglobulins in the

clotting-lysis mixtures differed.

Thus, in System 5, the second lot

of euglobulins (precipitated at pH 5.9) was used in a concentration
4 times that of the first lot with System 4 (precipitated at pH 5.4).
Concentrations of SK in the 2 systems differed slightly —

in System

4, final SK concentration was 6.5 units/ml; in System 5, 6.8 units/ml.
Rapid lysis of the clots with such low concentration of SK is
explained in large measure by the reduction in concentration of
inhibitors of fibrinolysis in preparing the euglobulins from the
human plasma used.

Before making decisions concerning concentrations

of iJK to be routinely used in System 4 and in System 5, correlation
cuv-ves were constructed from data on fibrinolysis times of mixtures
using a given sample of dog plasma and varying concentrations of SK
(Fig. 3 for correlation curve on V-l, using first euglobulin
preparation). '
Thrombelastographic analysis of SK-activated fibrinolysis of dog
plasma.

A thrombelastogram of SK-activated fibrinolysis of platelet-

poor citrated dog plasma is represented in Fig. 4*

Fibrinolysis time,

beginning from the time of clotting to complete lysis, was measured
in millimeters from the end of the reaction time, r, to a point, f,
at which the light had stopped all movement, representing the complete

1.0

Log

Fibrinolysis

Time
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Log [SK]

Fig. 3.

Correlation curve relating SK concentration and
fibrinolysis times. Data were obtained on tests
with plasma from a normal adult dog (V-l), using human
euglobulins as proactivator.

*

18

20 mm

Fig. 4.

ma

Thrombelastogram illustrating’ SK-activated fibrinolysis.
The clot-lysis mixture contained platelet-poor plasma
from an adult hemophilic dog (G-3), a human euglobulin
fraction, CaCl2 » and streptokinase.
On diagram:,
r, reaction time; k, clot formation time; ma, maximum
amplitude; f, end of fibrinolysis.
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lysis of the clot.

Since the film moved at 2 mm/min while being

exposed in the thrombelastograph, the above measurement was divided
f

by 2 to convert the fibrinolysis time measured in millimeters to
fibrinolysis time expressed in minutes.
The maximum amplitude, a representation of clot firmness, is the
greatest distance in millimeters between the two branches of the
thrombelastogram.

The maximum amplitude for normal platelet-poor

citrated human plasma is considered to be 20 mm.

Arbitrarily, 20 mm

was chosen to be the end of k, clot formation time (deNicola, 1957).
Statistical Analysis.

An analysis of variance was used to test

statistically the effect of choline on fibrinolysis in the dog.
The general least squares procedure was used in order to remove the
effects due to disproportionate sub-class numbers as well as to remove
the effects due to the co-variables, the day of choline administration
and the number of platelets in the plasma.

The variables subjected

to this analysis were differences in control and choline test period
fibrinolysis times and in control and choline test period maximum
amplitudes.

To obtain observations as measured for the above

variables, values for the control period were averaged, and this
average subtracted from the corresponding observed value for each
day of choline treatment.

In using the following model for

determining population, all the estimates were independent.
model for the analysis of variance is as follows:
Yijkl = > + si + Dij + pk + 0 1 <xi jkl “ *) +

01

(x ijkl " x)2

C ijkl

+ 03

(x ijkl “ x>3 +

The
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where
Y^jki is observation as measured

p

is mean of observations as measured
is effect of "i"

D ij

is effect of "j"(individual) dog within "i"
is effect of "kM

fix

status (hemophilic or normal)
status

system of 5 systems used

is partial linear regression coefficient

xijkl *s day of "I” observation on "k" procedure

of

"j" dog in "i" status
x

is mean day of observation

^ 2

is partial quadratic regression coefficient

fi 3

is partial cubic regression coefficient

£

ijkl ds random error due to all variables not accounted
for previously

To test for statistically significant differences due to the
status of the dog, the day of choline treatment, and the procedure
used, F values were calculated from the above estimates (F = variance
ratio).
To test for statistically significant differences due to the effect
of choline on fibrinolysis times and maximum amplitudes, t values were
calculated (t = least squares mean ).
standard error
In all cases of statistical analysis, statistical significance
was considered only at the 1% level of probability.

RESULTS

Major characteristics of thrombelastograms obtained with
plasma from dogs during the control periods; influence of SK
concentration and of the form In which human proactivator supplied.
With mixtures containing human plasma as source of proactivator,
influence of SK concentration was conspicuous.in shifting
fibrinolysis times.

Plasma samples from 2 dogs (V-l and G-4)

were tested with each of the 3 concentrations of SK.

Plotting

of log fibrinolysis time versus log concentrations of SK produces
essentially a straight line (Fig. 5), as was found by Astrup
(1965)

using purified reagents.

Mean fibrinolysis times for

dog V-l obtained with mixtures containing 14.7, 38.5, and 29.1
SK units/ml (Systems 1, 2, and 3) were 133, 12, and 51 min, res
pectively.

For dog G-4, comparable values were 183, 25, and 73 min,

respectively (Table 1).

For both dogs, the maximum amplitudes

developed with the lowest and the intermediate concentrations of SK
were considered satisfactory; with 38.5 units/ml (System 2), however,
maximum amplitudes were sometimes less than 20 mm (Table 2) .

Data

obtained on dogs G-3, K-l, K-2, and K-3 with Systems 2 and 3
followed the trends described for V-l and G-4.

Clots prepared with

plasma from the young dogs (K-l, K-2, K-3) lysed somewhat faster than
those with plasma from adult dogs.

Also, clots containing plasma

oSystem 1

a System 2
A System 3

Log

Fibrinolysis

Time

2.5

2.0

1.5

1.0
1.1

1.2

1.3

1.4

1.5

1.6

Log (SK]
Fig. 5.

Relation between SK concentration and fibrinolysis times. Data were
obtained on tests with plasma from adult normal dog (V-l), using human
plasma as proactivator. Influence of choline on SK activity is
exhibited by shift in position of the curve.
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Table 1.

Fibrinolysis times for dogs during control period, choline treatment, and after choline
treatment. Values given are means for the number of observations indicated in parentheses.
Times for the period after treatment are for samples collected 5 or more days after
discontinuance of choline.

Fibrinolysis Times (minutes)
G-39
K-2cf
K-ld*

System

Choline

Period

G-4d*

1

300 mg/dose

Control
Choline*
After

183(6)
509(6)
172(3)

133(7)
221(6)
117(4)

2

600 mg/dose

Control
Choline
After

25(3)
61(3)
19(2)

16(4)
44(3)
14(2)

27(1)
92(3)
23(2)

15(3)
33(2)
21(3).

9(3)
28(2)
16(3)

14(3)
23(2)
25(3)

3

300 mg/dose

Control
Choline*
After

73(3)
279(3)
74(2)

51(3)
155(3)
55(2)

86(1)
285(3)
108(2)

36(2)
125(2)
64(3)

29(3)
110(2)
44(3)

48(3)
75(2)
58(3)

4

300 mg/dose

Control.
Choline
After

13(1)
62(3)
14(1)

13(1)
50(2)
13(1)

10(1)
36(2)
13(1)

20(1)
86(2)
13(1)

14(1)
44(3)
7(1)

5a

300 mg/dose

Control
Choline*
After

54(3)
158(5)
77(2)

28(3)
50(3)
117(5) --- 189(3)
39(2)
21(2)

25(3)
88(5)
28(2)

5b

600 mg/dose

Control
Choline*

77(2)
180(3)

V-lcf

25(2)
81(3)
11(1)

*Statistically significant at 1% level.

• •• • •

44(3)
113(5)
84(2)

45(3)
121(5)
23(2).
23(2)
93(3)

21(2)
48(2)

K-3c?

39(2)
90(2)

A-lcf

•e • •
• •• •

Table 2.

System

Maximum amplitudes for dogs during control period, choline treatment, and after choline
treatment. Values given are means for the number of observations indicated in parentheses.
Measurements for the period after treatment are for samples collected 5 days or more after
discontinuance of choline.

Choline

Period

Maximum Amplitudes (millimeters)
G-32
K-2c?
K-lcf

K-3cT

G-4d*

V-lc?

37(6).
32(6)
32(3)

31(7)
30(6)
33(4)

•• ••
• •• •
•• ••

• •• •
• •• •
• #• •

• •• •
•• • •
•• • •

•• ••
•• ••
• •• •

A-Id*

1

300 mg/dose

Control
Choline
After

2

600 mg/dose

Control
Choline*
After

23(3)
27(3)
20(3)

21(4)
24(3)
19(2)

26(1)
34(3)
25(2)

16(3)
24(2)
23(3)

16(3)
20 (2)
19(3)

17(3)
20 (2)
22(3)

3

600 mg/dose

Control
Choline
After

32(3)
30(3)
28(2)

21(3)
27(3)
27(2)

33(1)
37(3)
37(2)

22(2)
28(2)
28(3)

19(3)
26(2)
25(3)

20(3)
27(2)
29(3)

4

300 mg/dose

Control
Choline*
After

15(2)
21(3)
11(1)

•• • o
•• • •
•• • •

8(1)
15(3)
10(1)

12(1)
23(2)
17(1)

11(1)
20(2)
14(1)

11(1)
17(2)
9(1)

11(2)
16(3)
5(1)

300 mg/dose

Control
Choline*
After

34(3)
47(5)
34(2)

•• • •
•• • •
•• • •

27(3)
47(5)
35(2)

35(3)
52(5)
31(2)

33(3)
44(5)
26(2)

34(3)
35(5)
35(2)

29(3)
38(5)
35(2)

Control
Choline*

34(2)
38(3)

•• • •
••••

••• ••
•••

31(2)
. 36(2)

26(2)
28(2)

35(2)
...37(2)

35(2)
32(2)

5a

5b

600 mg/dose

*Statistically significant at 1% level.
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from V-l (normal adult dog) lysed more rapidly than did those with
plasma from G-3 or G-4 (hemophilic adult dogs), but whether
characteristic differences in fibrinolysis times between adult normal
and hemophilic dogs of this colony occur cannot be determined from
the 3 dogs tested.

There was no significant difference between

hemophilic and normal dog fibrinolysis times and maximum amplitudes
as measured in all 5 systems tested (Table 4).
With the concentration of SK chosen for use with the first
euglobulin preparation (System 4), lysis times ranged from 1 0 - 2 5
min in the 6 dogs tested (G-3, G-4, A-l, K-l, K-2, K-3).

Maximum

amplitudes were rather low (8-15 mm).
With clot-lysis mixtures designated as System 5 (containing
the second euglobulin preparation in relatively high concentration),
SK was used at almost the same concentration as in the preceding
series.

Average maximum amplitudes attained in thrombelastograms

of the 6 dogs tested ranged from 27 - 34 mm, more than twice those
shown with System 4.

Fibrinolysis times were also increased,

average values ranging from 25 - 54 minutes.
Effect of choline on thrombelastograms.

Statistical analysis

combining all 5 test systems showed that choline administration
significantly increased fibrinolysis times and maximum amplitudes
as measured (Table 3).

Only Systems 2 and 4 did not demonstrate a

significant increase in fibrinolysis times even though the mean
fibrinolysis times were more than or almost doubled in every case.
This lack of statistical significance may be because the fibrino
lysis times of Systems 2 and 4 were shorter in general than those

Table 3.

Statistical analysis of differences in fibrinolysis times and
maximum amplitudes between control and choline periods. Analysis
includes all variations introduced while making observations.

Variant
Fibrinolysis:
Choline
minus
control
Maximum Amplitude:
Choline
minus
control

Least-Squares
Mean

106

161.82

15.25

12.58*

106

4.23

1.11

3.81*

*Statistically significant at 1% level.

Standard
Error

t
Value

Number of
Observations

Table 4.

Analysis of variance on data for fibrinolysis times and maximum amplitudes, testing
for differences due to status of dog and system used.

Variant
Fibrinolysis:
Choline
minus
Control

Source of
Variation
(VS)

Degree of
Freedom
(DF)

Sum of
Squares
(SS)

Mean
Squares
(MS)

Variance
Ratio
(F)

1

126366

126366

2.60

4

1424449

356112

21.89*

17.8

0.186

256.4

5.68*

Between Status
(Hemophilic or normal)
Between Procedures

Maximum Amplitude: Between Status
Choline
(Hemophilic or normal)
minus
control
Between Procedures

*Statistically significant at 1% level.

1

17.8

4

1025.7

of the other systems, resulting in a smaller least squares mean
while still having approximately the same standard error.

Table 1

illustrates the mean fibrinolysis times and those times for choline
periods found significantly different from control periods.

In

System 2, the maximum amplitudes are significantly increased, while
Systems 1 and 3 do not demonstrate this effect.

Maximum amplitudes

during choline treatment are 20 mm or more in almost every case
(Table 2).
In the first euglobulin mixture (System 4, 6.5 SK units/ml),
mean fibrinolysis times range from 36-81 min in the same dogs
previously tested without choline treatment (Table 1).

Mean

maximum amplitudes are all significantly increased into a range of
15-23 m m (Table 2).
System 5 (euglobulin mixture containing 6.8 SK units/ml)
p'roduced mean fibrinolysis times of dogs on choline treatment
ranging from 88-159 min, and mean maximum amplitudes of 35-52 mm.
Fibrinolysis times and maximum amplitudes are both significantly
increased (Tables 1 and 2).
Thrombelastograms after discontinuance of choline.

With

samples collected 5 days or more after choline treatment, fibrino
lysis times and maximum amplitudes for the majority of the dogs
were in the range noted before choline treatment.

System 1 produced

a mean fibrinolysis time of 172 min and a mean maximum amplitude of
32 for G-4; for dog V-l, 117 min and 33 mm.

Systems 2 and 3 provide

data which follows the trends described for dogs G-4 and V-l
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(Tables 1 and 2).

Fibrinolysis times of those samples collected

5 days or longer after choline treatment decreased significantly
from those times measured during choline treatment.

No

significant decrease in maximum amplitudes in the plasmas collected
5 days or longer after cessation of choline was observed.
In System 4 the mean fibrinolysis times for all the dogs tested
ranged from 7 - 1 4 min, slightly lower than the range found before
choline treatment but not significantly lower than during choline
treatment.

Mean maximum amplitudes range from 5 - 1 7 mm, lower

than during choline treatment but not significantly so.
Mean fibrinolysis times in System 5 after choline treatment
range from 21 - 35 mm.

These values represent a significant

decrease from those obtained when the dogs were on choline.

There

are no statistically significant differences between the "before"
and "after" fibrinolysis times and maximum amplitudes in any of the
experiments.
Effect of platelet numbers.

Although the dog platelet-poor

plasma samples contained varying numbers of platelets, no effect
of platelet numbers could be correlated with fibrinolysis times.
A negative linear regression coefficient (-0.6057), relating
differences between control and test period maximum amplitudes
with platelet numbers, supported the correlation that as platelet
numbers in the plasma sample increased, the differences between
control and test period maximum amplitudes decreased.
Comparison of fibrinolysis times for choline administered at
five times the normal dietary level and ten times the normal dietary
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level.

In addition to 1 period in which 6 dogs were given 5 times

the normal dietary level of choline, 5 of the dogs were given twice
that amount of choline while using the same system, System 5.
Differences for the fibrinolysis times between the 2 treatments are
not significant.
Effect of system used.

Significant differences between both

the fibrinolysis times and maximum amplitudes recorded in the various
systems used were found (Table 4).

That is to say, the testing

system can be adjusted to provide data within desired ranges of
measurement.
Effect of citric acid.

Citric acid in amounts equivalent

to the citrate in choline citrate at 10 times the normal dietary
level of choline was given to 6 dogs (G-3, G-4, K-l, K-2, K-3, V-l)
to test the effect of citrate ions on fibrinolysis times.

Using

Systems 2 and 3, an increase in fibrinolysis times was not observed.
With System 2, the mean fibrinolysis time for the 6 dogs during
control period was 20 min with a standard deviation of * 6; for
citric acid test period, 16 i 5 min.

With System 3, the mean

fibrinolysis time for the control period was 72 + 21 min; for
Citric acid test period, 50 "t 12 min.

One-half of the above dose

of citric acid was given to 3 dogs (A-l, K-l, K-2).

The mean

fibrinolysis time, using System 5, was 24 * 7 min for the control
period;

22 1" 7 min for the citric acid test period.

Of 15 observations made during citric acid treatment, an
increase in fibrinolysis time occurred in 1 case, in another there
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was no change, and in the remaining 13, the fibrinolysis times
were less than during the control period.
Effect of choline treatment of euglobulin clot lysis times.
To supplement the information gathered on fibrinolysis times with
the thrombelastograph, euglobulin clot lysis times were measured
with some of the plasmas obtained for use on the thrombelastograph
while using System 5.

This supplementary information was obtained

in order to have an additional measure of fibrinolytic activity or
experimental inhibition of it.
Six dogs (G-4, G-3, A-l, K-l, K-2, K-3) administered choline
at 5 times the normal dietary level had a mean euglobulin clot lysis
t.
_r
time of 83 min with a standard deviation of T 11. The mean
euglobulin clot lysis time for samples collected 5 days or more

+

after stoppage of choline administration was 29 _ 8 min.

Five

dogs (G-4, AtI, K-l, K-2, K-3) were then given choline at twice
the above dosage and had a mean euglobulin clot lysis time of
35 i 4 min, as compared to a control period mean of 28 I- 3 min.
Euglobulin clot lysis times were significantly increased by
choline in both of the above experiments.
Influence of EACA on thrombelastographic patterns.
of EACA, 0.34 mg/kg, was given to 2 normal dogs.

One dose

Using System 5,

fibrinolysis times during a non-treatment period for adult normal
dog V-l and young normal K-9 were 18 and 33 min, respectively.
Three hours after 1 peroral dose of EACA, fibrinolysis times
increased to 190 min for dog V-l and 300 min for dog K-9.

Seven

hours after another dose 5 days later, the times were much shorter —
V-l, 60 min; K-9, 110 min.

The following day, the times were even
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lower, approaching the non-treatment values.

Maximum amplitudes

were increased after the 3-hour dose and lessened during the
following observations described above.
Epsilon - aminocaproic acid had great inhibition on
fibrinolysis in vivo a short time after ingestion and absorption.
Fibrinolytic inhibition by EACA diminishes markedly after 3 hours
(Niewiarowski and Wolosowicz, 1966).

DISCUSSION

It is yet to be demonstrated without question that hemophilic
bleeding can be partially controlled with perorally administered
drugs which do not alter the clotting mechanisms.

But the

theoretical basis for such is at hand, and is supported by the
studies here reported.

The theory of Astrup et al. (I960) suggests •

that while there is a dynamic balance between continuous fibrin
formation and fibrinolysis in normal people, in hemophilia the
balance is upset by retarded fibrin formation while fibrinolysis
is essentially normal but possibly acting on the slowly formed
fibrin to prevent proper hemostasis.

Therefore, hemophilic bleeding

might be partially controlled by prolonging fibrinolysis, thus
partially restoring the dynamic hemostatic balance.
Choline, shown to be a major ingredient of peanut extracts
which shorten bleeding time, is here revealed as a substance which
can delay fibrinolysis, both as measured by the euglobulin clot
lysis method, and as measured by thrombelastographic recording of
streptokinase-activated fibrinolysis of plasma clots.

A possible

benefit to hemophiliacs of prolonged fibrinolysis is more than
retention of a slow-forming clot:

Retardation of fibrinolysis is

important to enable the clot to form in the first place.

When

fibrinolysis was quickly activated with SK mixtures in this study,
33
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even normal dog blood failed to clot enough to enlarge the
thrombelastogram.

With the SK mixtures, it was necessary to cause

the hemophilic dog blood to clot before full activation of fibrino
lysis.

Otherwise, the mixture exhibited no clotting on the

thrombelastograms.

It seems that as clotting began, the incipient

clot was unable to form because of concurrent fibrinolysis.

Support

for this idea comes from observations that thrombelastograms of a
sample of dog plasma without SK always indicated a more elastic clot
(higher maximum amplitudes) than did a substitute sample of the same
plasma treated with SK.

The slightly lowered elasticity of the

latter could be the result of slight early initiation of some
fibrinolysis while clotting was proceeding.
Streptokinase-activated fibrinolysis parallels natural activa
tion of fibrinolysis in the body in that the SK-proactivator
complex activates plasminogen, converting it into plasmin.

One may

compare this type fibrinolysis with that initiated by adding plasmin
directly to the system.

In the latter case, the maintenance of a

maximum amplitude on the thrombelastogram would not occur.

The

thrombelastographic patterns produced by plasmin and activators of
plasminogen are distinctly different (Astrup and Egeblad, 1965).
There is slight evidence that choline treatment may indeed be
hemostatic in hemophilic dogs.

During 2 choline treatment periods

the toenails of the adult male bleeder (G-4) were clipped closely
to induce bleeding.

The bleeding from toenails stopped permanently

in less than 3 hours in both cases.

The immature male bleeder (A-l)

had his toenails clipped similarly but was not under choline
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treatment in one case.

His toenails bled for 10 hours before

choline was finally administered late at night and the bleeding was
stopped by the next morning.

At another time though, when under

choline treatment, this young dog did bleed intermittently from
a clipped toenail for 24 hours.

However, he was very active and

the bleeding was more a rebleeding through disturbance of the
wound.

Before choline treatment, his fibrinolysis times were rather

short; under treatment they became about as long as the normal times
of the other dogs.

On another occasion this dog had a large

ecchymosis or hematoma which was progressively getting larger in
his neck where a venipuncture had been performed.

He was then

treated with choline and after 1 day the enlargement seemed to
stop, and after 3 days the blue coloration had disappeared and there
was a hard thrombus where the bleeding had occurred.

In another

case, dog G-4, was observed to be bleeding as evidenced by the
presence of blood in his feces and by a low hematocrit.

Fibrino

lysis times indicated enhanced fibrinolytic activity (Fig. 6).

He

was treated with choline and 3 days later his fibrinolysis times
were greatly increased, indicating decreased fibrinolytic activity.
His feces were also observed to appear normal.

Eight days after

the last dose of choline, fibrinolysis times had returned to a
normal range, although never as short as they had been during the
bleeding period.

These observations, while not proving the

hemostatic action of choline, do suggest that further investigations
are in order.

A
-O'

B
iii

1

Fig. 6.
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Thrombelastograms demonstrating effects of choline and of SK concentration on
fibrinolysis. Patterns are for adult hemophilic dog (G-4), using human euglobulin
fraction as source of proactivator and of clotting factors. In each of the three
groups, the top recording is for the highest SK concentration.
A. Five hours before
choline. At this time dog had blood in feces and low hematocrit. Fibrinolysis time
shorter than usual control valves.
B. After 3 days of choline treatment.
C. Eight
days after last dose of choline.
co
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While the above discussion may imply that choline treatment
might relieve difficult cases of bleeding, any beneficial effect
of choline may be overridden by increased fibrinolytic action
caused by stress, such as excessive loss of blood, repeated blood
sampling, trauma, strenuous exercise, and even possibly excessive
alcoholic consumption.

Fearnley, Ferguson, Chakrabarti, and

Vincent (1960) reported increased fibrinolytic activity of blood
after beer consumption.

During the early phase of one period of

choline administration, my test dogs were bled daily, and larger
than usual volumes were taken.

This period was not included in

the results because the daily sampling caused a rapid decrease in
fibrinolysis times.

The same dogs were continued on choline

treatment without interruption and subsequently they were bled
every other day.

The clot lysis times during this second period

significantly became prolonged (this was System 5, reported above).
Celander and Celander (1968) report increased fibrinolytic activity
in dogs resulting from daily bleedings.
Another implication that might arise is that excessive
choline consumption in normal subjects may result in depression
of fibrinolysis so that interference with resolution of thrombotic
deposits in the vascular system may occur.

This interference

could possibly manifest itself in resultant pathology of the cardio
vascular system.
This study is a first attempt at studying fibrinolysis of
hemophilic blood using thrombelastography.
modify techniques previously used.

It was necessary to

The first problem was the
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formation of a satisfactory clot before clot lysis occurred.
Thrombin was not useful because a satisfactory maximum amplitude
could not be obtained.

My choice of the several activators of

fibrinolysis was streptokinase.

Urokinase proved to be

unsatisfactory using whole blood because clot lysis was not uniform
and high levels of urokinase were needed.

With streptokinase, it

was necessary to use a human source of proactivator.

Human

diagnostic plasma provided proactivator and clotting factors for
hemophilic plasma but contained some undesirable factors (e.g.,
inhibitors of fibrinolysis).

Some advantage was gained by

selecting human euglobulins as a source of proactivator and of
clotting factors for hemophilic plasma.

Much less SK was needed

with the euglobulins (Systems 4 and 5).
This study employed platelet-poor dog plasma because the
platelet-rich clots in the thrombelastograph produced large
maximum amplitudes, and lysed irregularly, in that the clots would
break away from walls of the cuvettes.

A level of platelets of

3000/mm^ or so produced satisfactory clots that lysed smoothly.
A higher platelet level of 10000 to 20000/mm^ is undesirable in
that it tends to mask the higher maximum amplitude values of choline
treated anima'ls.

These higher maximum amplitudes are interpreted

to signify that choline treatment delays fibrinolysis in the test
system long enough for the maximum amplitude to be reached.
Since choline was used in the citrate form, it was necessary •
to explore the effect of the citrate alone on fibrinolysis.
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Although the results seemed to indicate no statistical difference
in fibrinolysis times between untreated and citrate-treated dogs,
the times with citrate were shorter.

There may be a high dosage

level at which the citrate may interfere with the choline effect.
It appears that choline prolongs fibrinolysis only after it
has been metabolized.

Though the choline delayed fibrinolysis

times, the delay appeared within 24 hours, but the effect did not
manifest itself as quickly as did the effect of EACA, which was
evidenced 3 hours after administration.

The action of EACA is as

a direct inhibition of plasminogen activation (Alkjaersig, Fletcher,
and Sherry, 1959; Ablondi, Hagan, Philips and DeRenzo, 1959).
Choline, like EACA, also seems to mediate inhibition of plasminogen
activation.

In thrombelastographic analysis, persistence of a

constant maximum amplitude for a short while before visible lysis
' is evidence that plasminogen activation is delayed (Astrup and
Egeblad, 1965).

Also, a shift in the curve in the log plot of

fibrinolysis time vs. SK concentration indicates that a constant
percentage of SK is rendered ineffective by choline, suggesting that
inhibition of fibrinolysis is acting at the plasminogen activation
level.

Although it seems that choline may be inhibiting the

activation of plasminogen, the mechanism is unknown.
Figure 7 illustrates the difference between thrombelastograms
of SK-activated clot lysis and of lack of lysis of dog plasma clot
and the effect of plasmin activity on maximum amplitude.

The

maximum amplitude of the unlysed plasma clot is higher than that

no lysis

Thrombelastogram
amplitude
(mm)

lysis

Time
Increase in
Plasmin Activity
(Arbitrary units)

Fig. 7.

Schematic representation of dynamics of SK-activated fibrinolysis.
text for discussion.

See

■
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of the clot which lyses.

The difference in maximum amplitudes is

a measure of the activity of plasmin, as shown below the zero line.
The activity of plasmin occurs after plasminogen activation.

A

small initial activation probably occurs, followed by an increasing
later activation which causes the clot to lyse more rapidly.
Although choline is acting as an antagonist to SK-activated
fibrinolysis, observations on the bleeding episodes of the dogs
mentioned previously and the prolonged euglobulin clot lysis times
indicate that the choline effect is not restricted to inhibition of
SK-activated fibrinolysis.
An understanding of the action of choline in fibrinolysis
will likely come when it is known through which of the roles the
effect is mediated:

1) methyl donor;

2) lipotropic agent;

3) precursor to phosphatidyl ethanolamine, which is a known
' inhibitor of fibrinolysis (Reid et al., 1965), or 4) any of the
other roles choline may play in metabolism.
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